| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1694 | 2019 |
| A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer RE Buller, IB Runnebaum, BY Karlan, JA Horowitz, M Shahin, T Buekers, ... Cancer gene therapy 9 (7), 553-566, 2002 | 246 | 2002 |
| Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017 VN Giri, KE Knudsen, WK Kelly, W Abida, GL Andriole, CH Bangma, ... Journal of Clinical Oncology 36 (4), 414, 2018 | 207 | 2018 |
| Dostarlimab for primary advanced or recurrent endometrial cancer MR Mirza, DM Chase, BM Slomovitz, R dePont Christensen, Z Novák, ... New England Journal of Medicine 388 (23), 2145-2158, 2023 | 203 | 2023 |
| Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy AK Sood, MS Shahin, JI Sorosky Gynecologic oncology 83 (3), 599-600, 2001 | 197 | 2001 |
| The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma MS Shahin, JH Hughes, AK Sood, RE Buller Cancer: Interdisciplinary International Journal of the American Cancer …, 2000 | 185 | 2000 |
| Pembrolizumab plus chemotherapy in advanced endometrial cancer RN Eskander, MW Sill, L Beffa, RG Moore, JM Hope, FB Musa, R Mannel, ... New England Journal of Medicine 388 (23), 2159-2170, 2023 | 171 | 2023 |
| A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary … RL Coleman, WE Brady, DS McMeekin, PG Rose, JT Soper, SS Lentz, ... Gynecologic oncology 122 (1), 111-115, 2011 | 132 | 2011 |
| Anorectal dysfunction after surgical treatment for cervical cancer AK Sood, I Nygaard, MS Shahin, JI Sorosky, SK Lutgendorf, SSC Rao Journal of the American College of Surgeons 195 (4), 513-519, 2002 | 123 | 2002 |
| Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 RE Buller, MS Shahin, JA Horowitz, IB Runnebaum, V Mahavni, ... Cancer gene therapy 9 (7), 567-572, 2002 | 100 | 2002 |
| Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study RJ Schilder, WE Brady, HA Lankes, JV Fiorica, MS Shahin, XC Zhou, ... Gynecologic oncology 127 (1), 70-74, 2012 | 81 | 2012 |
| Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial I Vergote, G Scambia, DM O'Malley, B Van Calster, SY Park, ... The lancet oncology 20 (6), 862-876, 2019 | 78 | 2019 |
| Failure of BRCA1 dysfunction to alter ovarian cancer survival RE Buller, MS Shahin, JP Geisler, M Zogg, BR De Young, CS Davis Clinical cancer research 8 (5), 1196-1202, 2002 | 66 | 2002 |
| A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology/gynecologic oncology group study (GOG-254) JK Chan, W Brady, BJ Monk, J Brown, MS Shahin, PG Rose, JH Kim, ... Gynecologic oncology 150 (2), 247-252, 2018 | 65 | 2018 |
| The p53 Mutational Spectrum Associated with BRCA1 Mutant Ovarian Cancer RE Buller, TA Lallas, MS Shahin, AK Sood, M Hatterman-Zogg, ... Clinical cancer research 7 (4), 831-838, 2001 | 50 | 2001 |
| A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study TF Rocereto, WE Brady, MS Shahin, JS Hoffman, L Small, J Rotmensch, ... Gynecologic oncology 116 (3), 332-334, 2010 | 48 | 2010 |
| A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study BE Miller, JA Blessing, FB Stehman, MS Shahin, SD Yamada, AA Secord, ... Gynecologic oncology 118 (2), 139-144, 2010 | 45 | 2010 |
| The Glutathione S-Transferase M1 Genotype in Ovarian Cancer TA Lallas, SK McClain, MS Shahin, RE Buller Cancer Epidemiology Biomarkers & Prevention 9 (6), 587-590, 2000 | 44 | 2000 |
| A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic … LP Martin, M Sill, MS Shahin, M Powell, P DiSilvestro, LM Landrum, ... Gynecologic oncology 132 (3), 526-530, 2014 | 43 | 2014 |
| A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study … TJ Herzog, MW Sill, JL Walker, D O'Malley, M Shahin, K DeGeest, ... Gynecologic oncology 120 (3), 454-458, 2011 | 36 | 2011 |
